 Home > Active Ingredient News > Drugs Articles > Just now, GlaxoSmithKline "Mepolizumab" was approved in China

Just now, GlaxoSmithKline "Mepolizumab" was approved in China

 Last Update: 2021-12-06
 Source: Internet
 Author: User

Tags

diet ibs patients

pca enzymatic treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, China’s National Food and Drug Administration (NMPA) announced that GlaxoSmithKline (GSK)’s mepolizumab (mepolizumab, formerly known as mepolizumab) injection has been approved for marketing in China
.

Mepolizumab is a "first-in-class" anti-IL-5 humanized monoclonal antibody and the world's first approved anti-IL-5 monoclonal antibody

Mepolizumab is a "first-in-class" anti-IL-5 humanized monoclonal antibody, and it is also the world's first approved anti-IL-5 monoclonal antibody against IL-5 eosinophilic granulomatosis.

Screenshot source: NMPA official website

Mepolizumab is an anti-IL-5 antibody, which can selectively recognize and bind IL-5, block the binding of IL-5 to the receptor on the surface of eosinophils, and reduce the growth of eosinophils It is expected to alleviate a variety of diseases caused by excessive eosinophils
.

In the United States, the FDA has approved a number of indications for mepolizumab, including severe asthma, adult patients with eosinophilic granulomatous vasculitis, adults and children over 12 years of age with eosinophilia (HES) patients , accompanied by nasal polyps and chronic sinusitis (CRSwNP) patients, and so on
.

In China, the marketing application of mepolizumab was accepted by the CDE in July 2020 and was included in the priority review
.

According to the public information of priority review, the indication for this application of the drug is: it is suitable for adult patients with eosinophilic granulomatous polyangiitis

Suitable for adult patients with eosinophilic granulomatous polyangiitis

Screenshot source: CDE official website

According to the clinical trial data of the drug approved in the United States for the treatment of this indication, compared with placebo , patients receiving mepolizumab have a significantly longer accumulation time for remission
.

In the 36th and 48th weeks of treatment, the proportion of patients receiving mepolizumab in remission was significantly higher than that in the placebo group

, The accumulation time for patients receiving mepolizumab to achieve remission was significantly prolonged

Eosinophilic granulomatous polyangiitis is a rare autoimmune disease
.

Its symptoms include asthma, high levels of eosinophils, and inflammation of medium and small blood vessels

Reference materials:

[1] On November 19, 2021, the drug approval document pending information is released.

[1] On November 19, 2021, the drug approval document pending information is released.
Retrieved Nov 19, 2021, from https:// ] The FDA today approved the first new drug for rare vasculitis.
Retrieved Dec 13, 2017, from https://mp.
weixin.
qq.
com/s?__biz=MzAwMDA5NTIxNQ==&mid=2649968375&idx=6&sn=61700633b5e3a28fb506751594e8a416&chksm=82e9c87730050sccd15cccd15e8a416&chksm=82e9c877300e

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.